FDA recalls Kinevac injectable drug due to manufacturing temperature deviation
FDA is recalling Kinevac (Sincalide for Injection), a prescription injectable drug distributed nationwide, due to cGMP deviations involving temperature abuse during manufacturing.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall for a risk-of-harm product (prescription intravenous medication) subject to manufacturing temperature abuse. Although no illnesses or injuries have been reported, temperature deviation could compromise product stability or integrity.
Plain-English summary
FDA is recalling Kinevac (Sincalide for Injection) supplied as 5 micrograms per vial, 10 vials per box, manufactured by Bracco Diagnostics Inc. and distributed by McKesson Medical-Surgical Inc. The recall involves 5 boxes distributed nationwide. This is a prescription injectable medication administered intravenously.
The recall was initiated due to cGMP (current Good Manufacturing Practice) deviations related to temperature abuse during manufacturing.
McKesson Medical-Surgical Inc. has notified customers of the recall. The company is unable to identify specific lot numbers received by individual customers, though each customer received notification with the distribution date and the dates when impacted product may have been shipped.
Patients and healthcare providers should contact McKesson Medical-Surgical Inc. or their healthcare provider with questions about this recall.
The recalled product
- Product
- KINEVAC (SINCALIDE)
- Brand
- KINEVAC
- Manufacturer
- Mckesson Medical-Surgical Inc. Corporate Office
- Category
- Drug — Injectable / Diagnostic
- Hazard
- temperature-exposure
- stability-compromise
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModeratePovi-One Povidone-Iodine 10% Topical Drug Recall for Sub Potency
FDA (Drugs) · 2026-07-01
- ModerateSensipar cinacalcet hydrochloride tablets recalled for CGMP deviations
FDA (Drugs) · 2026-07-01
- ModerateSensipar Cinacalcet Tablets Recalled Due to CGMP Deviations
FDA (Drugs) · 2026-07-01
- ModerateSensipar (Cinacalcet Hydrochloride) Tablets Recalled for CGMP Deviations
FDA (Drugs) · 2026-07-01